Format

Send to

Choose Destination
BMC Cancer. 2017 Nov 6;17(1):718. doi: 10.1186/s12885-017-3715-5.

Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.

Author information

1
Division of Molecular Pathology, The Institute of Cancer Research, London, UK. Vallari.shah@icr.ac.uk.
2
Department of Haemato-Oncology, Royal Marsden Hospital, London, UK.
3
Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
4
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Abstract

BACKGROUND:

Multiple Myeloma is a cancer of plasma cells associated with significantly reduced survival. Long term survivorship from myeloma is very rare and despite advances in its treatment the disease is generally considered incurable. We report a patient diagnosed with myeloma carrying a germline mutation of a tumour suppressor gene who has effectively been cured.

CASE PRESENTATION:

A 36-year-old woman was diagnosed with IgG lambda myeloma in 1985. She was treated with melphalan chemotherapy followed by high-dose melphalan and autologous stem cell rescue and since remained in complete remission despite not having received any additional therapy. After eliciting a prior history of multiple primary melanomas and breast cancer, she was tested for and shown to be a carrier for a germline mutation in CDKN2A.

CONCLUSIONS:

This is the second case report of germline mutation of CDKN2A being associated with myeloma. CDKN2A is a stabiliser of p53. Long term survivorship after high dose DNA damaging chemotherapy with melphalan in this patient is compatible with an increased chemo-sensitivity due to impairment of the DNA repair pathway.

KEYWORDS:

CDKN2A; Germline mutation; Myeloma; Survival

PMID:
29110637
PMCID:
PMC5674776
DOI:
10.1186/s12885-017-3715-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center